Facial volume and contour: Fat Transfer vs Filler: Which Lasts Longer?

The Aesthetic Society describes a small donor incision, local anesthetic and a cannula connected to a syringe. Cleveland Clinic names belly, hips and thighs as usual donor areas.

Fat is separated and prepared before transfer. The Society describes filtration or centrifugation as alternatives. Neither label promises how much volume will remain.

The Society describes small parcels placed as the cannula withdraws. Recipient areas and the amount harvested must appear separately in your plan.

Cleveland Clinic says fat transfer is not a weight-loss procedure and does not produce a drastic donor-site change. Ask whether the proposed harvest is only enough to supply the graft or includes a separately planned contouring operation. Those scopes can mean different scars, soreness and charges. A facial photograph alone leaves the donor-site part of the decision unanswered. The liposuction guides explain a broader harvest and contouring plan.

A hollow, a shadow, a crease and tissue that has descended can occupy the same region. Stanford lists paranasal areas and nasolabial folds, while the Dallas technique article describes volume restoration as distinct from correcting gravitational descent or skin wrinkles. Ask your surgeon to point out what produces the feature you want changed, including what happens when you smile. More volume should have a stated purpose and a limit you understand.

The Aesthetic Society requires donor tissue for the proposed volume. A small facial goal still needs a harvest assessment; a photograph cannot establish sufficiency.

The Society lists good health, no smoking and no circulation problems. Report diagnoses, nicotine use, prescriptions and supplements so the team can assess healing and anesthesia.

ASPS’s July 2026 interview favors stable or near-target weight. It gives no validated waiting period or GLP-1-specific eligibility rule.

The 2022 retrospective study of 416 facial-grafting patients associated lower BMI with more donor complications at mean 6.2 months. This does not establish a BMI threshold.

Cleveland Clinic lists near-ideal weight, realistic expectations and not smoking or quitting. ASPS’s July 2026 interview favors stable or near-target weight because living graft tissue can enlarge or shrink. It sets no fixed waiting period after weight loss and supplies no GLP-1 trial. ASPS’s December 2024 smoking reference suggests considering at least four weeks of cessation, with individual judgment; it is general perioperative guidance rather than a facial-retention threshold. Discuss nicotine and medication changes with the surgical and prescribing teams. If avoiding surgery or treating descent is your main priority, ask what a filler or lift could reasonably address instead.

ASPS says fat injection is more extensive than packaged filler because it includes donor liposuction, additional donor discomfort and potentially weeks of healing. It also describes less predictable results and possible repeats. HA is an absorbable sugar-based material. PLLA is a biodegradable synthetic polymer with gradual effects over weeks. Sculptra is a PLLA product, rather than another name for a fat graft. FDA warns that removal of some fillers can be difficult or impossible; neither comparison establishes an easy way to remove unwanted facial fat.

FDA’s April 25, 2023 Sculptra cheek supplement names “fine lines and wrinkles in the cheek region” in “immune-competent subjects.” The FDA-hosted label says periorbital injection has not been studied, lip safety and effectiveness have not been evaluated, and not to inject the red vermilion. It warns against overcorrection because effects develop over several weeks and describes delayed papules or nodules. These are product-specific statements. They neither approve under-eye fat grafting nor describe every HA product’s label.

Hassan and colleagues’ July 2026 indexed meta-analysis abstract includes nine comparative studies and 805 participants. Its satisfaction standardized mean difference is 0.91, with a 95% confidence interval from −0.32 to 2.14 and substantial heterogeneity. Because that interval includes zero, the estimate does not establish a clear satisfaction advantage for fat. A standardized score difference is not the percentage of people satisfied. Common follow-up and a US-specific subgroup are not supplied in the abstract.

The midface studies measured regional volume with three-dimensional imaging. The 2009 prospective series had 33 people and 66 regions, with mean follow-up of 16 months. The 2014 membrane-filtration series had 26 women and 52 hemi-midfaces, with mean follow-up of 17 months. Its historical centrifugation comparison was not randomized. Those studies cannot isolate processing from every other difference between treatment eras. Nor are two sides of a face two independent patients.

The 2021 analysis found that measurement method significantly affected retention estimates. The 2016 evidence review had already noted the absence of a standard test for viability or volume augmentation. The 2022 ITR2 series observed decline and later rebound in 29 women, but its uncontrolled zone-volume endpoint cannot prove that resorbed grafts grow back. A small study’s lack of a significant weight-change association does not establish that future large weight changes leave the result unchanged.

ASPS describes about half surviving, Stanford approximately 60%, and an ASPS-hosted July 2026 interview estimates 65–70%. Those pages give no patient denominator, measurement method or common follow-up for those figures. Cleveland Clinic’s under-eye page also describes about half being absorbed without a study. The study table keeps measured findings separate from these counseling estimates. Long-lived tissue can coexist with continued aging, weight-related change and a later wish for additional treatment.

The 2018 UC Davis review describes small deposits across tissue planes. The drawing illustrates contact with vascularized tissue, without marking a safe injection route.

The 2020 vascularization review describes early tissue-fluid support followed by new vessels. Living graft tissue needs that support; some placed fat can be lost.

Faded parcels represent possible resorption. Their number is illustrative and must not be read as a percentage of fat that survives.

The original 2013 paper examined three laboratory fat preparations and found no viable adipocytes in its nanofat sample. This does not establish clinical regeneration or equivalence to volume-bearing fat.

The Aesthetic Society describes small parcels deposited in tissue planes. The UC Davis review describes gentle deposits across multiple planes and passes to increase contact with vascularized tissue. The vascularization review describes early support through tissue fluid followed by new vessel formation. The drawing shows those relationships schematically. It supplies neither a recommended injection depth nor a safe route around facial vessels. A parcel drawn pale represents possible loss, without assigning a fraction to your result.

Intact-fat volume restoration and emulsified nanofat are different preparations. The original 2013 nanofat article analyzed three laboratory fat preparations and reported no viable adipocytes in its nanofat sample. That observation cautions against treating the names as interchangeable. It does not establish a clinical stem-cell effect. The 2022 supplementation review rated 20 of 27 facial studies weak, six moderate and one strong, and concluded that additive benefit remained unclear. Recovery products, diets or added treatments in personal stories cannot supply missing controlled evidence.

Cleveland Clinic describes a facial examination, goals and photographs before treatment. In the accompanying explanation, Paul Phelps distinguishes harvesting fat from elsewhere from moving nearby eyelid fat as a flap. Ask which operation is proposed and whether blepharoplasty is also involved. The 2023 US retrospective referral series examined 48 people with lumps or contour irregularities at mean 14-month follow-up. Grafted tissue was separate from native eyelid fat, sometimes within orbicularis. A series selected for complications cannot tell you the chance of developing one.

The 2021 periorbital review includes 39 studies and 4,046 overall cases, with orbital reconstruction, dermis-fat procedures and combined eyelid operations. Its satisfaction estimate uses 27 studies, including four with combined patient/surgeon assessment. Its complication analysis uses 37 papers, with varying follow-up. Those are different endpoint sets; the overall enrollment cannot be assigned to either percentage as a response denominator. The review is not a US injection-only cosmetic under-eye cohort.

Cleveland Clinic describes complete results taking up to four months, but elsewhere on the same page describes absorption over four to six months. These are counseling statements rather than one measured settling deadline. The Clinic lists vision changes and stroke signs, including one-sided weakness, as reasons to call the provider. Contact your provider right away for these changes. The vascular-risk chapter below explains why a reassuring photograph or a low general complication percentage cannot rule out serious injury.

The review separates restoration of volume from repositioning or removal of lax tissue. The Dallas technique article similarly distinguishes grafting from correcting gravitational descent and skin wrinkles. A proposed facelift may already redistribute tissue into a hollow-looking region. Ask the surgeon to explain which volume deficit would remain and where added fullness could become unwanted. The linked facelift guides compare operative scope; this chapter does not repeat their face-and-neck technique decisions.

The Dallas perioral study’s unequal baseline wrinkle scores and different treatment eras limit a causal claim. Its abstract says minimum one year and Methods says average one year; there is no individual follow-up distribution. A 2015 ASPS-member survey found 85.2% of 309 respondents used grafting with facelifts. That counts questionnaire responses, without a response denominator in the abstract, rather than proving superiority or describing all US operations. The 2014 midface study found lower retention with accompanying rhytidectomy in an observational subgroup; it cannot prove that a facelift causes graft loss.

The UC Davis technique review favors low-pressure harvest and centrifugation. The 2016 evidence review places less emphasis on washing versus centrifuging. Another review distinguishes laboratory and animal findings from human comparisons, and concludes that they have not produced a universal clinical protocol. These source differences should remain visible. Ask which part of the proposed process has been compared in patients receiving treatment in your area, with measured outcomes at an appropriate follow-up.

The 2019 split-treatment trial involved ten patients, face/hand sites and imaging over one year, with SMAS plication in some faces. It did not find a statistically significant PRP volume advantage. This is a small mixed-site study, rather than proof of no possible effect or a reliable benefit. Do not convert a clinician’s preferred preparation, a patient’s recovery-product routine or a device’s ability to handle fat into evidence of improved long-term take.

FDA’s May 28, 2020 REVOLVE ENVI clearance describes aspiration, harvest, filtering and transfer of autologous adipose tissue. Its indications specify reimplantation without additional manipulation. That is a device function and indication, without a patient retention denominator. It cannot establish efficacy of added cells, certify every preparation sold under a clinic’s name or approve a regenerative treatment. Get the exact technique and any extra charge in writing before comparing quotes.

The 2022 hand review’s complication table concerns 300 patients in nine studies. Its overall 320-patient enrollment includes another study and cannot be substituted as the denominator. The dusky discoloration-or-ecchymosis category includes more than bruising. The paper’s satisfaction reporting is internally inconsistent, with 254 stated satisfaction patients but 244 across the categorical-scale cohorts. We therefore do not present its satisfaction percentage as the chance you will be happy. The authors call for validated questionnaires, objective volume measurement and longer follow-up.

Washington University describes filling divots using liposuctioned fat. The Aesthetic Society also lists depressions after liposuction and scars. Neither supplies a defect-specific success rate.

The 2020 US multicenter blinded trial treated 17 subjects with paired body scars. Fourteen attended at 12 months; three six-month values were carried forward. It detected no significant fat-versus-saline difference.

The 2018 uncontrolled series followed 12 patients with subcision plus fat through 12 months. Improved movement cannot isolate the effect of fat or establish facial retention.

Buttock fat transfer and breast augmentation require their own candidacy discussions. Face, hand and contour-depression evidence here does not supply those outcomes.

The 2020 trial had 14 twelve-month assessments and carried forward three six-month values. It was planned for 19 subjects and treated scars at body sites rather than an adult facial acne-scar cohort. A failure to detect superiority does not prove equivalence or establish a stem-cell mechanism. The 2018 twelve-patient burn-scar series combined subcision and fat, so it cannot isolate fat’s effect. The 2025 burn review also describes mixed interventions and predominantly uncontrolled assessments. A scar promise needs evidence for that exact indication.

GRAFT records medical complications, rather than every suboptimal cosmetic result or request for additional volume. Across all sites, 38% of baseline procedures lacked follow-up, and reported visits had a median of 25 days; that is visit timing, not equal follow-up for every patient. The registry is predominantly US, with 50 international baseline procedures, and acknowledges that serious events or deaths may be omitted. The followed-facial denominator is derived from Table 7, rather than the baseline face-area count or all-site enrollment.

The 2026 necrosis review describes nodules, oil cysts and lipogranuloma across 18 mostly case-based studies, without an incidence denominator or common follow-up. Firm painless nodules may appear weeks to months after grafting. A lump is not automatically necrosis; the surgeon needs to assess it. The donor study also identifies contour irregularity, prolonged firmness and redness. The Society notes small donor incisions may leave visible scars or lighter/darker marks. A small access point does not mean there is no donor-site tradeoff.

Cleveland Clinic’s August 2022 fat-transfer guidance says to call the plastic surgeon immediately for excessive bleeding, incision redness or heat, persistent dizziness, severe nausea or vomiting, sudden or persistent sharp pain, or incision leakage. Contact your surgeon right away for these symptoms. Do not use the percentages in the table to decide a new symptom can wait. Ask before surgery who answers after hours and where an in-person assessment can occur.

The embolism review also reports six deaths among its case collection and found insufficient high-quality data for an evidence-based treatment algorithm. The 2024 review’s 58 events in 38 affected patients likewise does not count all procedures performed. Calling the event uncommon does not justify inventing a numerical probability. The 2022 complications review even has conflicting intravascular-event totals, 40 of 298 in its abstract and 87 of 354 in its Results table. Those are shares of reported events, neither a risk among all graft recipients.

The 2026 ultrasound review includes 12 studies and 885 patients, mostly observational and single-center, with no uniform follow-up in the indexed abstract. An absence of reported catastrophic events cannot establish that ultrasound eliminates them. The layer drawing on this page is not a safe injection map. Ask the operating surgeon about anatomical planning, recognition of vascular injury and the actual escalation arrangement. Neither this evidence nor the case reviews establish a reliable way to dissolve or reverse a fat embolus.

Cleveland Clinic’s under-eye guidance lists vision changes and stroke signs, including one-sided weakness, as reasons to call the provider. Contact your provider right away for those symptoms. Separately, FDA’s filler guidance advises immediate medical attention for unusual pain, vision changes, pale/gray/blue skin or stroke signs during or shortly after filler injection. That is FDA guidance for fillers, not evidence of a fat-embolus rescue protocol. Confirm your team’s urgent response plan before agreeing to treatment.

The Aesthetic Society says repeat treatment may be needed. In the 2009 prospective midface series, eight of 33 patients had touch-ups at mean 16-month follow-up. This is one selected practice series.

The 2023 referral study examined 48 problem patients. It distinguishes graft tissue from native eyelid fat; remote appearance alone cannot diagnose the cause of a contour change.

ASPS’s July 2026 interview describes graft growth and shrinkage with weight. Additional treatment can have several reasons; the study above is not a national failure rate.

The 2016 ASPS-copyrighted consent template asks readers to discuss repeat-treatment costs. It is a practice-hosted reference, not a current clinical standard or a promise of free revision.

A later session may address limited retained volume, a deliberately staged goal or subsequent change in weight and appearance. The Society says some fat may not take and several months may be needed for an accurate picture. ASPS’s July 2026 interview says living fat can grow or shrink and changing facial volume may lead to more treatment. No fixed waiting period, universal repeat schedule or probability of needing another session follows from those pages. Ask your surgeon how they distinguish early swelling from a persistent contour concern.

The 48-patient lower-eyelid referral series describes selected problems, rather than a reliable correction-success rate. An assessment may need the original sites, amounts, preparation, accompanying surgery and earlier photographs. FDA says Kybella is approved only for submental fat in adults. That is not approval to undo facial grafts. Its warning about unapproved fat-dissolving injections describes serious infections, cysts, scarring and deformity. Do not turn online suggestions about massage, dieting or injections into a plan for removing unwanted grafts.

The practice-hosted 2016 ASPS-copyrighted facial-fat consent template warns about loss of volume, possible additional treatment and repeat-treatment charges. It describes itself as a reference, not a standard of care. A discount on one component does not settle anesthesia, facility or other bills. Ask what reassessment involves, what healing interval the surgeon would use and which charges would recur. The cost guide keeps those quote questions separate from an outcome promise.

The Aesthetic Society advises asking about experience, the setting, anesthesia and options if goals are unmet. Ask who personally harvests, processes and places the fat and which specialty board you can check.

The Society describes an accredited hospital, ambulatory facility or office surgical suite. For outpatient treatment it calls for a driver and help for at least the first 24 hours.

FDA’s June 3, 2021 warning names unapproved regenerative products, including fat-derived stromal vascular fraction. “Your own cells” does not establish regulatory approval.

FDA’s May 2020 REVOLVE ENVI device clearance describes tissue handling. It cannot establish approval or effectiveness of a stem-cell rejuvenation treatment.

The Society describes local anesthesia with IV sedation as likely, and general anesthesia as sometimes desirable. Cleveland Clinic says larger areas or combined surgery can change the anesthetic plan. The Society recommends a driver and help for at least the first 24 hours after outpatient treatment. This is education without a patient-outcome denominator. Get your own written helper, discharge and after-hours contact arrangements.

FDA’s warning concerns unapproved regenerative products even when sourced from the person’s own body, including fat-derived stromal vascular fraction. It describes approval/licensure and oversight requirements and reports blindness, tumors and infections from products within that warning, without an exposed-patient denominator. These are not ordinary facial-fat incidence rates. A processing-device clearance cannot supply missing therapy approval. If cell manipulation or a regenerative add-on is proposed, ask for the exact product, intended use and applicable FDA documentation rather than relying on the marketing name.

The Aesthetic Society recommends examples similar to your own anatomy and goals. Include the donor-site result when harvesting is part of the decision.

Ask whether the case also had a facelift, eyelid surgery, skin resurfacing or later injections. A combined photograph cannot isolate how much the graft changed.

Cleveland Clinic says apparent facial results may appear in one to two weeks before later volume loss. These are educational estimates without a cohort, checked October 16, 2026.

Use matching views and ask about expression, light, camera distance, makeup and later treatment. Photographs support a goal discussion; the 2009 imaging study needed three-dimensional measurement to estimate volume in 33 people.

Start with the Afters fat-transfer photo collection, then ask the operating surgeon for cases with similar hollows, donor limitations and desired fullness. Check whether lifting, upper or lower eyelid surgery, laser, peels or later injections contributed. Ask when each photograph was taken and whether weight changed. A photograph of an appealing combined result cannot attribute its eye area, skin quality or overall change to fat alone. Request donor views if their appearance matters to your decision.

The Society recommends discussing experience, anesthesia, location, recovery, costs and options if goals are unmet. Fat transfer to face cost depends on sites, technique and harvesting scope; the linked cost guide compares posted prices with their inclusions. Fat transfer recovery involves both donor and recipient sites; the linked recovery guide separates those milestones. Stanford explicitly excepts fat transfer from its no-time-off statement for packaged fillers. Save the questions that matter, including where you want no extra volume and how you would feel about another procedure.